Circio’s circular RNA platform posts strong eye and heart data, backed by oversubscribed funding

Targovax ASA ( (GB:0RIS) ) just unveiled an announcement.

Circio Holding ASA reported new in vivo data showing that its latest AAV-circVec 4.0 construct can deliver up to 50-fold higher gene expression in the eye than conventional mRNA-based AAV vectors, even maintaining a tenfold advantage at a 90% lower dose. The company also confirmed earlier findings of roughly 40-fold enhanced gene expression in the heart and high cellular uptake, reinforcing circVec’s potential to make AAV gene therapies more potent, safer and cheaper in high‑need cardiac and ophthalmic indications.

To accelerate development of this platform, Circio raised NOK 68.6 million in an oversubscribed rights issue and private placements, extending its funding runway and enabling team expansion in Stockholm. Management said the strong in vivo data, combined with a recently announced R&D collaboration with a global pharma partner, underpin efforts to hit key scientific milestones and pursue new business development opportunities in the competitive gene therapy field.

More about Targovax ASA

Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform, developed by subsidiary Circio AB in Stockholm, is designed to boost RNA stability and protein expression, targeting applications across genetic medicine, cell therapy and chronic diseases.

Average Trading Volume: 4,564,984

Current Market Cap: NOK420.2M

See more insights into 0RIS stock on TipRanks’ Stock Analysis page.